Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03869957
Other study ID # 2846
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 1, 2019
Est. completion date June 30, 2022

Study information

Verified date March 2023
Source Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Randomized, double-blind, controlled clinical trial to evaluate the effect of parenteral nutrition (PN) supplemented with lipid emulsions containing 0.1-0.2 g omega 3 polyunsaturated fatty acids (n-3 PUFA)/kg body weight/day for 7 days on malondialdehyde (MDA) levels, a marker of lipoperoxidation of reactive species, compared with a control group (without n-3 PUFA) in patients with intestinal failure (IF).


Description:

IF is the loss of intestinal function that affects the decrease in the absorption of macronutrients, water, and electrolytes, so it requires intravenous supplementation such as PN and/or intravenous fluids to maintain health and/or growth. IF type II is associated with complex infectious and metabolic complications and patients require PN for weeks or months. Long-term PN use, however, includes the risk of complications, among which a serious one is the intestinal failure-associated liver disease (1). It has been proposed that metabolic endotoxemia (2-3), inflammation (4) and oxidative stress (5) are involved in the development of this intestinal failure-associated liver disease. Although some studies have reported beneficial effects of n-3 PUFA to prevent and reverse the liver disease associated with IF (6-7), due to its antioxidant (8-10) and anti-inflammatory activity (11-12) and in the modulation of the intestinal microbiota (13), the literature on the use of n-3 PUFA in non-critical patients with IF and PN is limited and the results have not been conclusive. Therefore, a randomized, double-blind, controlled clinical trial to evaluate the effect of PN supplemented with lipid emulsions containing n-3 PUFA/kg body weight/day for 7 days on oxidative stress (concentrations of MDA), compared with a control group (without n-3 PUFA) will be performed.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date June 30, 2022
Est. primary completion date May 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients admitted in the non-critical areas of the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ) with a nutritional risk between January 2019 and July 2020 will be considered eligible. - Patients with recent diagnosis of IF type II (an evolution >28 days) originate from various gastrointestinal or systemic diseases (short bowel, intestinal fistula, intestinal dysmotility, mechanical obstruction, and extensive small bowel mucosal disease). Exclusion Criteria: - Patients with contraindications for PN - Patients with known allergies to the components of the PN formula - Severe liver or renal insufficiency - Uncontrolled diabetes mellitus - Certain acute and life-threatening conditions - Immunological diseases (such as autoimmune diseases, human immunodeficiency virus infection, cancer, etc.) - Those that take immunosuppressant medications - Severe hemorrhagic disorders - Pregnant or lactating

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Intervention group
0.1-0.2 g n-3 PUFA/kg body weight/day for 7 days

Locations

Country Name City State
Mexico Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán Ciudad de México Tlalpan

Sponsors (1)

Lead Sponsor Collaborator
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Country where clinical trial is conducted

Mexico, 

References & Publications (13)

Burns DL, Gill BM. Reversal of parenteral nutrition-associated liver disease with a fish oil-based lipid emulsion (Omegaven) in an adult dependent on home parenteral nutrition. JPEN J Parenter Enteral Nutr. 2013 Mar;37(2):274-80. doi: 10.1177/014860711245 — View Citation

Cadenas S, Cadenas AM. Fighting the stranger-antioxidant protection against endotoxin toxicity. Toxicology. 2002 Oct 30;180(1):45-63. doi: 10.1016/s0300-483x(02)00381-5. — View Citation

Calder PC. Omega-3 fatty acids and inflammatory processes: from molecules to man. Biochem Soc Trans. 2017 Oct 15;45(5):1105-1115. doi: 10.1042/BST20160474. Epub 2017 Sep 12. — View Citation

Giordano E, Visioli F. Long-chain omega 3 fatty acids: molecular bases of potential antioxidant actions. Prostaglandins Leukot Essent Fatty Acids. 2014 Jan;90(1):1-4. doi: 10.1016/j.plefa.2013.11.002. Epub 2013 Dec 3. — View Citation

Korpela K, Mutanen A, Salonen A, Savilahti E, de Vos WM, Pakarinen MP. Intestinal Microbiota Signatures Associated With Histological Liver Steatosis in Pediatric-Onset Intestinal Failure. JPEN J Parenter Enteral Nutr. 2017 Feb;41(2):238-248. doi: 10.1177/ — View Citation

Lacaille F, Gupte G, Colomb V, D'Antiga L, Hartman C, Hojsak I, Kolacek S, Puntis J, Shamir R; ESPGHAN Working Group of Intestinal Failure and Intestinal Transplantation. Intestinal failure-associated liver disease: a position paper of the ESPGHAN Working — View Citation

Laparra JM, Sanz Y. Interactions of gut microbiota with functional food components and nutraceuticals. Pharmacol Res. 2010 Mar;61(3):219-25. doi: 10.1016/j.phrs.2009.11.001. Epub 2009 Nov 13. — View Citation

Nandivada P, Fell GL, Gura KM, Puder M. Lipid emulsions in the treatment and prevention of parenteral nutrition-associated liver disease in infants and children. Am J Clin Nutr. 2016 Feb;103(2):629S-34S. doi: 10.3945/ajcn.114.103986. Epub 2016 Jan 20. — View Citation

Omata J, Pierre JF, Heneghan AF, Tsao FH, Sano Y, Jonker MA, Kudsk KA. Parenteral nutrition suppresses the bactericidal response of the small intestine. Surgery. 2013 Jan;153(1):17-24. doi: 10.1016/j.surg.2012.04.001. Epub 2012 Jun 13. — View Citation

Osowska S, Kunecki M, Sobocki J, Tokarczyk J, Majewska K, Omidi M, Radkowski M, Fisk HL, Calder PC. Effect of changing the lipid component of home parenteral nutrition in adults. Clin Nutr. 2019 Jun;38(3):1355-1361. doi: 10.1016/j.clnu.2018.05.028. Epub 2 — View Citation

Pironi L, Arends J, Baxter J, Bozzetti F, Pelaez RB, Cuerda C, Forbes A, Gabe S, Gillanders L, Holst M, Jeppesen PB, Joly F, Kelly D, Klek S, Irtun O, Olde Damink SW, Panisic M, Rasmussen HH, Staun M, Szczepanek K, Van Gossum A, Wanten G, Schneider SM, Sh — View Citation

Ventro G, Chen M, Yang Y, Harmon CM. Molecular impact of omega 3 fatty acids on lipopolysaccharide-mediated liver damage. J Pediatr Surg. 2016 Jun;51(6):1039-43. doi: 10.1016/j.jpedsurg.2016.02.078. Epub 2016 Mar 2. — View Citation

Wu G, Zhou W, Zhao J, Pan X, Sun Y, Xu H, Shi P, Geng C, Gao L, Tian X. Matrine alleviates lipopolysaccharide-induced intestinal inflammation and oxidative stress via CCR7 signal. Oncotarget. 2017 Feb 14;8(7):11621-11628. doi: 10.18632/oncotarget.14598. — View Citation

* Note: There are 13 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary Change of malondialdehyde (MDA) in serum from baseline to day 7 Measurement of malondialdehyde (MDA) that is a marker for oxidative stress, determined in serum in ng/dl. Change from baseline (day 0) at day 7
Secondary Change of glutathione (GSH) in plasma from baseline to day 7 Measurement of glutathione (GSH) that is a marker for oxidative stress, determined in plasma in micromol/l. Change from baseline (day 0) at day 7
Secondary Change of oxidized glutathione (GSSG) in plasma from baseline to day 7 Measurement of oxidized glutathione (GSSG) that is a marker for oxidative stress, determined in plasma in micromol/l. Change from baseline (day 0) at day 7
Secondary Change of GSH/GSSG ratio from baseline to day 7 GSH and GSSG will be combined to report GSH/GSSG ratio in micromol/l Change from baseline (day 0) at day 7
Secondary Change of carbonylated protein in serum from baseline to day 7. Measurement of carbonylated protein that is a marker for oxidative stress, determined in serum in nmol/mg Change from day 0 at day 7.
Secondary Change of lipopolysaccharide (LPS) in serum from baseline to day 7. Measurement of lipopolysaccharide (LPS) that is a marker for metabolic endotoxemia, determined in serum in ng/dl. Change from baseline (day 0) at day 7
Secondary Change of C-reactive protein (CRP) in serum from baseline to day 7. Measurement of C-reactive protein (CRP) that is a marker for inflammation, determined in serum in pg/ml. Change from baseline (day 0) at day 7
Secondary Change of glucose in serum from baseline to day 7 Concentration of glucose in serum according medical records, in mg/dl Change from baseline (day 0) at day 7
Secondary Change of nitrogen ureic in serum from baseline to day 7 Concentration of nitrogen ureic in serum according medical records, in mg/dl Change from baseline (day 0) at day 7
Secondary Change of urea in serum from baseline to day 7 Concentration of urea in serum according medical records, in mg/dl Change from baseline (day 0) at day 7
Secondary Change of creatinin in serum from baseline to day 7 Concentration of creatinin in serum according medical records, in mg/dl Change from baseline (day 0) at day 7
Secondary Change of sodium in serum from baseline to day 7 Concentration of sodium in serum according medical records, in mmol/l Change from baseline (day 0) at day 7
Secondary Change of potassium in serum from baseline to day 7 Concentration of potassium in serum according medical records, in mmol/l Change from baseline (day 0) at day 7
Secondary Change of phosphorus in serum from baseline to day 7 Concentration of phosphorus in serum according medical records, in mg/dl Change from baseline (day 0) at day 7
Secondary Change of magnesium in serum from baseline to day 7 Concentration of magnesium in serum according medical records, in mg/dl Change from baseline (day 0) at day 7
Secondary Change of total bilirubin in serum from baseline to day 7 Concentration of total bilirubin in serum according medical records, in mg/dl Change from baseline (day 0) at day 7
Secondary Change of direct bilirubin in serum from baseline to day 7 Concentration of direct bilirubin in serum according medical records, in mg/dl Change from baseline (day 0) at day 7
Secondary Change of indirect bilirubin in serum from baseline to day 7 Concentration of indirect bilirubin in serum according medical records, in mg/dl Change from baseline (day 0) at day 7
Secondary Change of alanine aminotransferase in serum from baseline to day 7 Concentration of alanine aminotransferase in serum according medical records, in U/l Change from baseline (day 0) at day 7
Secondary Change of aspartate aminotransferase in serum from baseline to day 7 Concentration of aspartate aminotransferase in serum according medical records, in U/l Change from baseline (day 0) at day 7
Secondary Change of alkaline phosphatase in serum from baseline to day 7 Concentration of alkaline phosphatase in serum according medical records, in U/l Change from baseline (day 0) at day 7
Secondary Frequency of patients with nutritional risk at baseline Determine the frequency of patients with nutritional risk according the Nutritional Risk Assesment-2002 (NRS-2002) tool, in percentage. At baseline (day 0)
Secondary Determine the type of intestinal failure at baseline. Identify the classification of patients with intestinal failure according the ESPEN guidelines on chronic intestinal failure in adults, in percentage. At baseline (day 0)
Secondary Frequency of primary diagnosis at baseline. Determine the frequency of primary diagnosis according medical records, in percentage. At baseline (day 0)
Secondary Assessment of resting energy expenditure at baseline Measurement of resting energy expenditure at baseline with a calorimeter, in kcal/day Baseline (day 0)
Secondary Assessment of nutritional prescription at baseline and at day 7 Determine the nutritional prescription at baseline, in kcal/day At baseline (day 0) and at day 7
Secondary Frequency of the type and characteristics of nutritional support administered Determine type and characteristics of nutritional support administered, according medical records, in percentage At baseline (day 0) and at day 7
Secondary Assessment of height at baseline Measurement of weight in centimeters Baseline (day 0)
Secondary Assessment of weight at baseline and at the end of the follow-up Measurement of weight in kilograms At baseline (day 0) and at the end of the follow-up (~ at day 30)
Secondary Assessment of body mass index at baseline and at the end of the follow-up Weight and height will be combined to report BMI in kg/m^2 At baseline (day 0) and at the end of the follow-up (~ at day 30)
Secondary Assessment of percentage of lean mass at baseline and at the end of the follow-up Measurement of percentage of lean mass at baseline with a electric bioimpedance (InBody S10 ®). At baseline (day 0) and at the end of the follow-up (~ at day 30)
Secondary Assessment of percentage of fat mass at baseline and at the end of the follow-up Measurement of percentage of fat mass at baseline with a electric bioimpedance (InBody S10 ®). At baseline (day 0) and at the end of the follow-up (~ at day 30)
Secondary Assessment of muscle function at baseline and at the end of the follow-up Measurement of muscle function with a handgrip at baseline, in kilograms At baseline (day 0) and at the end of the follow-up (~ at day 30)
Secondary Length of stay at hospitalization area Determine the length of stay from the date of admission to the date of discharge from the hospitalization area, in days From the date of admission to the date of discharge from the hospitalization area (~ at day 30)
Secondary Rate of mortality Evaluation of frequency of mortality, in percentage At the end of the follow-up (~ at day 30)
Secondary Frequency of intestinal failure-associated liver disease (IFALD) Determined with the elevation in alkaline phosphatase concentrations within the first 7-14 days with parenteral nutrition, by elevation in transaminase concentrations more than 1.5 times above the upper limit of reference, or by elevation in the total bilirubin or direct bilirubin concentrations >3, 4, 6 and 12 mg / dl From baseline (day 0) to the end of the follow-up (~ at day 30)
See also
  Status Clinical Trial Phase
Recruiting NCT04733066 - Quality of Life in Patients With Short Bowel Syndrome Treated Without and With Teduglutide - a Prospective Nested Matched Pair Analysis
Recruiting NCT05315765 - Development of a Patient Reported Outcome Measure for GastroIntestinal Recovery
Recruiting NCT04577456 - Chyme Reinfusion for Type 2 Intestinal Failure N/A
Recruiting NCT03590418 - Microbial Diversity of Small Bowel Stoma Effluent and Colonic Faeces
Completed NCT05909228 - Bone Markers in Pediatric IF
Recruiting NCT06283615 - Effect of Vitamin D on Skeletal Muscle Function and Qol in Patients With Chronic Intestinal Failure/Insufficiency N/A
Enrolling by invitation NCT06094504 - Spectral Lighting and Intestinal Failure N/A
Recruiting NCT05902104 - CGM-Assisted Management of PN
Completed NCT01386034 - Effects of Oral Citrulline on Protein Metabolism in Patients With Intestinal Failure (Citrugrêle 2) Phase 3
Recruiting NCT05868785 - Effect of Nocturnal Parenteral Nutrition on Bone Turnover and Energy Metabolism N/A
Terminated NCT01573286 - Safety and Dosing Study of Glucagon-like Peptide 2 (GLP-2) in Infants and Children With Intestinal Failure Phase 1/Phase 2
Active, not recruiting NCT00793195 - Can SMOFlipid®, A Composite Parenteral Nutrition Lipid Emulsion, Prevent Progression Of Parenteral Nutrition Associated Liver Disease In Infants? Phase 2
Recruiting NCT06169774 - Video Training Supplementation for Patients Discharged on Home Parental Nutrition N/A
Completed NCT03222232 - Catheter Salvage in Intestinal Failure Patients N/A
Completed NCT06391762 - Level of Deprivation Assessment in a Population of Short-bowel Syndrome Patients With Intestinal Failure
Completed NCT01986153 - Essential Fatty Acid Status & Immune Function in Parenteral Nutrition Patients N/A
Completed NCT00995813 - Pilot Study of the Rotavirus Vaccine in Infants With Intestinal Failure Phase 4
Recruiting NCT05813535 - 8.4% Sodium Bicarbonate Locks in Intestinal Failure Phase 2
Completed NCT00286039 - Plasma Citrulline Level in Relation to Absorptive Surface N/A
Completed NCT01946503 - Infant & Toddler Short Gut Feeding Outcomes Study